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INTRODUCTION:  Factor  VII deﬁciency  is a rare  cause  of  haemorrhagic  syndrome.  PRESENTATION  OF  CASE:
The authors  describe  a  case  of  a 48 years  old  patient  with  congenital  factor VII deﬁciency  suffering
abdominal  discomfort  diagnosed  as  gallstone,  that successfully  underwent  laparoscopic  cholecystectomy
with  continuous  infusion  of  Human  Prothrombin  Complex(PPSB)  around  the  procedure.vailable online 23 October 2016
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CONCLUSION:  The  usage  of  PPSB  solved  the  clotting  problems  enabling  the  surgical  procedure,  without
risks  for  the patient.
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. Introduction
Factor VII (FVII) is a vitamin K-dependent clotting factor that
s part of the extrinsic pathway of blood coagulation [1]. Congen-
tal FVII deﬁciency is a rare bleeding disorder. In patients with
ongenital FVII deﬁciency, bleeding manifestations and clinical
ndings vary widely, ranging from asymptomatic subjects to life
hreatening bleeding [1–3]. However, severe and life-threatening
emorrhaging is rare in general (about 5%) and occurs most fre-
uently during the ﬁrst six months of life [1,2]. Treatment has
raditionally involved FVII replacement therapy using fresh frozen
lasma, prothrombin complex concentrates or plasma FVII con-
entrates [2,3]. Intravenous administration of recombinant FVIIa
s now widely used for the treatment of FVII deﬁciency.
As FVII deﬁciency is a rare disease, experience with surgery in
VII-deﬁcient patients is limited. There have been some reports
escribing the use of recombinant activated FVII (rFVIIa) during
urgery in patients with congenital FVII deﬁciency [4–6]. Human
rothrombin Complex (PPSB) [7] contains coagulation factors II,
II, IX, X, so we  thought it could also be used as a substitute for
actor VII deﬁciency patients.
In this report, we describe a case of successful replacement treat-
ent with PPSB, without episodes of bleeding and thrombosis. This
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reativecommons.org/licenses/by-nc-nd/4.0/).is the ﬁrst report of the patient with congenital FVII deﬁciency
undergoing laparoscopic cholecystectomy with repeated admin-
istration of PPSB.
2. Case report
The patient was a 48-year-old man  (170 cm, 70 kg), he came
to our hospital suffering abdominal discomfort. After examina-
tion of abdominal ultrasound and CT scan, gallbladder stone was
conﬁrmed. His physical examination was  negative. He had no sig-
niﬁcant past medical history, he had never experienced a signiﬁcant
bleeding episode. His family history was  unremarkable.
We discussed treatment options with the patient, and planned
to perform the laparoscopic cholecystectomy. During pre-surgical
preparation, there were unexpected blood coagulation test ﬁnd-
ings. The prothrombin time (PT) was  32.1 s (reference range,
10.0–16.0 s) and the activated partial thromboplastin time (APTT)
was 26.5 s (reference range, 27.2–41.0 s). Other blood test results,
including those for liver and renal function, total protein were all
within normal range, and test for hepatitis B and C was negative.
As the PT was abnormal, while other tests were basically normal,
the consulting hematologist recommended more tests to conﬁrm
the diagnosis. FVII activity (FVII:C) was 2.7%, with no FVII inhibitor
activity, so he was diagnosed with congenital FVII deﬁciency.
We  worked out a plan to inject PPSB perioperatively, according
to the instruction for PPSB [7]. We  ﬁrst administered PPSB 1800U
(20–25U/kg [7]) intravenously before the surgery, and checked PT
and FVII:C. At that time, PT was 11.8 s, FVII:C was 51.4%, within nor-
mal  range and hematologist thought that was enough, so we  started
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Table  1
Parameters of coagulation function during perioperative period.
Date 2015−5-25 2015–6-5 2015-6-9 day of
surgery
2015–6-11
PT (s) 32.1 29.5 11.8 16.4
APTT (s). 26.5 23.2 24.6 25.4
FDP  (ug/mL) 2.5 3.92 3.23 2.52
D-dimer (mg/L) 0.2 0.1 0.1 2.4
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cINR  2.64 2.54 1.03 1.44
PLT  (109/L) 138 234 215
FVII:C 2.7 3.2 51.4
he operation. Laparoscopic cholecystectomy proceeded smoothly
nd took 20 min  with a total blood loss of 30 mL  900 U PPSB was
dministered intravenously every six hours [7] postoperatively for
he ﬁrst 48 h, cause the half-time of factor VII is 6–8 h [2,3]. PT, APTT,
nd levels of ﬁbrin degradation product (FDP) and D-dimer during
he clinical course are summarized (Table 1).
The patient was recovering well, and discharged from the hos-
ital two days after surgery without episodes of bleeding and
hrombosis. He is satisﬁed, and followed up by the surgeons at our
ospital.
. Conclusion
Here we described a very rare case of a FVII-deﬁcient patient
equiring PPSB for the laparoscopic cholecystectomy. Unfortu-
ately, the optimal dose and method of administration for PPSB
as not been established for various surgeries due to its rarity. The
ccumulation of cases of this disease in various ﬁelds is needed to
etermine the most appropriate replacement therapy.
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